Rapamycin Exerts Its Geroprotective Effects in the Ageing Human Immune System by Enhancing Resilience Against <scp>DNA</scp> Damage

Loren Kell, Eleanor J. Jones, Nima Gharahdaghi, Daniel J. Wilkinson, Kenny Smith, Andrew Philp, Adrian L. Smith, Lynne S. Cox, Ghada AlsalehAging 2026 · DOI

TL;DR

This study reveals that rapamycin, a known life-extending drug, protects the aging human immune system by directly enhancing resilience against DNA damage, rather than through previously assumed mechanisms like slowing protein synthesis or boosting autophagy. This "genoprotective" effect was demonstrated both in lab-grown human T cells and in an in vivo study with older adults, suggesting rapamycin could be a novel therapeutic for age-related immune decline and conditions driven by genome instability.

What Problem Does This Paper Address?

Rapamycin is a powerful geroprotector, extending lifespan across many species. While it's known to mitigate cellular senescence (a hallmark of aging), the precise mechanisms behind its benefits, especially in the human immune system, remain unclear. DNA damage is a major driver of immune aging (immunosenescence), which in turn accelerates overall organismal aging. Therefore, understanding how interventions like rapamycin impact genome stability within immune cells is crucial for developing effective anti-aging strategies. This paper aims to bridge this gap by investigating whether low-dose rapamycin can enhance genome stability in human immune cells and if this effect translates to older adults.

Methods

The researchers employed a multi-pronged approach:

  • In vitro genotoxicity assays: Human peripheral blood mononuclear cells (PBMCs), specifically T cells, were exposed to genotoxic agents (zeocin for double-strand breaks, hydrogen peroxide for general damage). They then used flow cytometry to measure markers of DNA damage (γH2AX), DNA damage response signaling (phosphorylated checkpoint kinases Chk1/Chk2, p53, p21), and mTOR activity (phosphorylated S6).
  • mTOR inhibition experiments: Rapamycin and another mTOR inhibitor (AZD8055) were used to assess their impact on DNA damage markers and response pathways in the genotoxic stress model.
  • Temporal analysis of rapamycin's effect: Cells were treated with rapamycin at different stages relative to genotoxic exposure (before, during, and after) to pinpoint when its protective effect occurs.
  • Assessment of cell cycle and protein synthesis: Standard techniques were used to rule out cell cycle arrest or inhibition of protein synthesis as the primary mechanisms of rapamycin's protection.
  • Autophagy flux analysis: Assays were conducted to determine if rapamycin's protective effect was mediated by enhanced autophagy.
  • Alkaline comet assay: This technique was used to directly measure DNA lesions in cells to assess genome stability.
  • Ex vivo analysis of aged immune cells: PBMCs from healthy older and younger donors were analyzed for markers of DNA damage, senescence, and mTOR activity to identify age-related changes.
  • In vivo clinical trial: A small, placebo-controlled study administered low-dose rapamycin to older adults. PBMCs were collected at various time points to assess changes in immune cell markers related to DNA damage, senescence, and mTOR activity.

Datasets

Not discussed in the paper. The study primarily uses primary human cells (PBMCs from healthy donors) and data from a small clinical trial.

Key Insights and Ideas

  • Direct Genoprotection by Rapamycin: The most significant finding is that rapamycin directly reduces DNA damage burden and improves cell survival, rather than acting indirectly through slowing protein synthesis, halting cell division, or stimulating autophagy. This is a novel mechanism for rapamycin's geroprotective effects.
  • mTOR Activity and DNA Damage are Linked: The study establishes a strong correlation between elevated DNA damage markers (γH2AX) and increased mTORC1 activity in T cells.
  • Age-Related Immune Cells Show Senescence and mTOR Hyperactivation: Aged immune cells from healthy donors exhibit a consistent enrichment of senescence markers and hyperactive mTOR signaling, suggesting they are prime targets for interventions.
  • Rapamycin's Protective Effect is Broad and Temporal: Rapamycin can protect against DNA damage regardless of whether it's administered before, during, or after genotoxic exposure, highlighting its robust protective capacity.
  • In Vivo Efficacy in Older Adults: The clinical trial demonstrated that low-dose rapamycin significantly reduced p21 (a marker of DNA damage-induced senescence) in immune cells of older adults, validating the in vitro findings.

Key Results

  • In vitro, rapamycin and AZD8055 significantly attenuated the increase in γH2AX (DNA damage marker) in T cells exposed to zeocin.
  • Rapamycin treatment reduced DNA lesion burden as measured by the alkaline comet assay, leading to a 3-fold greater cell survival 24 hours after genotoxic exposure compared to controls.
  • Ex vivo analysis revealed that aged immune cell subsets (TEMRA T cells, IgD-CD27- B cells, CD16+CD57+ NK cells, non-classical monocytes) showed elevated markers of DNA damage, senescence (especially p21), and mTOR activity.
  • In the in vivo study, immune cells from older adults treated with low-dose rapamycin showed a significant reduction in p21 levels compared to the placebo group.
  • The study ruled out cell cycle arrest, protein synthesis inhibition, and autophagy enhancement as the primary mechanisms of rapamycin's protective effect.

Limitations and Future Work

  • Small In Vivo Study Size: The in vivo study involved a small number of participants (4 on rapamycin, 5 on placebo), which the authors acknowledge limits the statistical power for some findings. Larger, phase 2/3 trials are suggested to confirm these effects.
  • Specific Immune Cell Subsets: While the study identified broad effects, further investigation into how rapamycin differentially impacts various immune cell subsets and their specific roles in aging and disease is warranted.
  • Long-Term Effects and Other Geroprotectors: The study focused on short-term genotoxic stress and 4-month rapamycin treatment. Exploring longer-term impacts and comparing rapamycin's effects with other geroprotectors (like spermidine) could reveal synergistic or distinct mechanisms.
  • Potential Side Effects: While low-dose rapamycin appeared non-immunosuppressive in this study, the authors caution that genoprotectors need careful consideration due to potential disruptions in immune cell removal of infected cells or tissue regeneration.

The authors propose that rapamycin's genoprotective mechanism opens new avenues for its use in contexts where genome instability drives pathology, including healthy aging, radiation exposure (e.g., cancer therapy, space travel), and infectious diseases.

Summary updated

Abstract

mTOR inhibitors such as rapamycin are among the most robust life-extending interventions known, yet the mechanisms underlying their geroprotective effects in humans remain incompletely understood. At non-immunosuppressive doses, these drugs are senomorphic, that is, they mitigate cellular senescence, but whether they protect genome stability itself has been unclear. Given that DNA damage is a major driver of immune ageing, and immune decline accelerates whole-organism ageing, we tested whether mTOR inhibition enhances genome stability. In human T cells exposed to acute genotoxic stress, we found that rapamycin and other mTOR inhibitors suppressed senescence not by slowing protein synthesis, halting cell division, or stimulating autophagy, but by directly reducing DNA lesional burden and improving cell survival. Ex vivo analysis of aged immune cells from healthy donors revealed a stark enrichment of markers for DNA damage, senescence, and mTORC hyperactivation, suggesting that human immune ageing may be amenable to intervention by low-dose mTOR inhibition. To test this in vivo, we conducted a placebo-controlled experimental medicine study in older adults administered with low-dose rapamycin. p21, a marker of DNA damage-induced senescence, was significantly reduced in immune cells from the rapamycin compared to placebo group. These findings reveal a previously unrecognised role for mTOR inhibition: direct genoprotection. This mechanism may help explain rapamycin's exceptional geroprotective profile and opens new avenues for its use in contexts where genome instability drives pathology, ranging from healthy ageing, clinical radiation exposure and even the hazards of cosmic radiation in space travel.
BibTeX
@inproceedings{kell2026rapamycin,
  author = {Loren Kell and Eleanor J. Jones and Nima Gharahdaghi and Daniel J. Wilkinson and Kenny Smith and Andrew Philp and Adrian L. Smith and Lynne S. Cox and Ghada Alsaleh},
  title = {{Rapamycin Exerts Its Geroprotective Effects in the Ageing Human Immune System by Enhancing Resilience Against <scp>DNA</scp> Damage}},
  booktitle = {Aging},
  year = {2026},
  doi = {10.1111/acel.70364},
}
Figure